ArticlePloS one2026
First-trimester plasma asprosin and its association with gestational diabetes mellitus: A prospective cohort study.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAsprosin a glucogenic adipokine associated with insulin resistance, has been found to be elevated in the plasma of women with gestational diabetes mellitus (GDM). Emerging evidence indicates that it can serve as a promising biomarker for the diagnosis of GDM during the second trimester. However, its utility in the first trimester has not yet been investigated. Therefore, the present study aimed to establish first-trimester reference ranges for plasma asprosin and to evaluate its predictive performance for the subsequent development of GDM.
methodsIn this prospective cohort study, low-risk women with singleton pregnancies at 10-14 weeks of gestation were consecutively enrolled. Participants with pregestational diabetes were excluded. Baseline clinical characteristics were documented, and blood samples were obtained for the measurement of plasma asprosin concentrations. The diagnosis of GDM at 24-28 weeks of gestation was established using the two-step screening approach.
resultsAmong the 302 participants, 98 (32.5%) developed GDM. Asprosin concentrations did not differ significantly across gestational ages between 10 and 14 weeks. However, asprosin levels increased significantly with maternal BMI (p < 0.001), demonstrating a quadratic relationship. A first-trimester reference range for plasma asprosin was established. Nevertheless, first-trimester asprosin showed poor predictive performance for subsequent GDM (AUC = 0.516), whereas maternal BMI and age showed modest predictive ability.
conclusionFirst, a reference range for first-trimester asprosin was established, which may serve as a valuable benchmark for future investigations examining various aspects of diabetes in pregnancy. Second, first-trimester asprosin concentrations did not discriminate between women who subsequently developed GDM and those who did not.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.